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The Progression of a Disease: an Overview of Schizophrenia. 
Lucas Stone 
 
 Schizophrenia is a psychotic disease that alters the way people perceive reality 
on a cognitive, social and or emotional level. First detection is often difficult because 
some of the patients have not had a history of psychosis before their first episode and to 
them; nothing is out of the ordinary. My aunt had adolescent onset schizophrenia which 
first was recognized when she was fourteen. She had recurring encounters with a man 
who was dressed in a rat suit and he became a familiar face to her. Unfortunately 
Melinda was the only person who could see the peculiar man in the rat suit. Adolescent 
onset is just one of the ways that schizophrenia can surface, often it does not surface 
until adulthood. On average men don’t have a psychotic episode until they are between 
17 and 27 and women are even later, with the majority of them not showing signs of 
psychosis until they are between 25 and 35.[1] Despite how common and widespread 
schizophrenia is, not very much is known about the disease and researchers around the 
world are trying to better understand it. Like most of diseases involving psychosis, 
schizophrenia was poorly treated and even more poorly understood until recently.[2] 
There were not effective pharmacological treatments for schizophrenic patients until the 
1950’s and those drugs had terrible side effects.[2] The aim of this paper is to provide 
an overview of schizophrenia, from what is known about the mechanism and the causes 
to the methods of treatment and detection. This information will then be used to propose 
possible future avenues of treatment, research and understanding. 
 
The Mechanism 
 The mechanism for schizophrenia has only been hypothesized. The question that 
needs to be answered is how does schizophrenia convince the mind that the stimuli it is 
receiving are coming from the physical world and not just from within the body. In his 
article, Kunjumon Vadakkan proposes that to achieve this requires a link between 
postsynapses so a signal can travel laterally through the synapses instead of in the 
prototypical fashion from axon to synapse.[3] In a normal collection of synapses there 
are ones associated with external pathways (physical sensations), ones confined to 
internal pathways within the mind and they are all separated by their plasma 
membranes.[3] In schizophrenia there might be something that causes the plasma 
membranes of synapses from external pathways and internal pathways to become 
fused in a way that allows for the passage of a signal from one postsynapse to 
another.[3] In this way the brain can perceive that it sees something tangible when there 
is actually nothing there.[3] Delusions such as the chronic paranoia are another 
common among symptom of schizophrenia and can work by the same mechanism.[3] 
 
Causes 
 The most intriguing research into the cause of schizophrenia revolves around the 
genetics component of the disease. Epidemiological studies have shown that 
schizophrenia is a heritable disease and this was confirmed by a concordance rate of 
60-70% between monozygotic twins.[4] Later studies looking at the sequence of 
patients with schizophrenia showed a common mutation was present within most of 
their genomes. The COMT gene was deleted.[1] The COMT gene controls a catabolic 
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enzyme involved in the degradation of dopamine and molecules and when it  is deleted 
a complex syndrome involving schizophrenia occurs.[1] While this mutation is common 
in many schizophrenic patients and it could be an important key in understanding the 
cause of this disease, there is conflicting data that shows that the COMT gene may 
have not have any role in schizophrenia.[1] The conflicting data as well as the 60-70% 
concordance rate between monozygotic twins suggests that there may be some form of 
epigenetic regulation as well occurring in schizophrenia.[4] Epigenetic regulation is a 
change in gene expression that is triggered by changes in the structure of the genome 
rather than changes to the actual sequence.[5] A frontal cortex tissue study to search 
for DNA methylation sites showed that there were highly active methylation sites next to 
regions involved in glutamatergic and GABAergic neurotransmission and brain 
development.[4] These factors have been linked with potential causes of schizophrenia; 
however, because the epigenetic component of schizophrenia is a recent idea, there 
has not been enough research yet to make concrete conclusions.[4]  
 
Detection 
 The invention of the MRI and specifically the fMRI (functional MRI) has 
remarkably helped diagnostic protocol for schizophrenic patients. By using fMRI, 
researchers have been able to study how the brains of schizophrenic patients respond 
differently to various stimuli in comparison to normal brains. Some studies have shown 
that abnormal frontotemporal system activity is integral to common cognitive problems 
in schizophrenia.[6] When stimulated with a more complex abnormal visual stimulation, 
schizophrenic brains have been shown to have a harder time processing the 
information.[6] The fMRI showed that the mid-frontal gyrus and the inferior frontal gyrus 
are more activated in schizophrenic patients than in the control subjects. In addition to 
impairing cognitive control, schizophrenia also affects the perception, interpretation, and 
processing of social information. Studies have shown that the overstimulation of the 
amygdala is a central part of the issue people with schizophrenia have with emotional 
processing.[6] While the right amygdala is stimulated in normal people when they see a 
positive or negative reaction on the faces of those around them, schizophrenic patients 
have bilateral amygala stimulation when they perceive a negative reaction.[6] A similar 
occurrence is true when patients have a stimulus for fear.[6] The overstimulation of the 
amygdala is linked to the lack of social control that is common in many schizophrenic 
patients. Because of the hotspots of activity that are generated during these stimulation 
tests, they provide a way to see if a patient’s brain has schizophrenic tendencies. This 
display of brain function allows doctors to possibly identify schizophrenia before the first 
episode of psychosis.  
 
Medication 
 The original psychosis drug was a dopamine receptor blocker called 
chlorpromazine and it was used because it was found to have calming activity on those 
with psychosis.[2] Similar dopamine inhibitors came out soon after but all of the first 
generation antipsychotics had the neurological side effects of parkinsonism (Parkinson’s 
disease like symptoms) or dyskinesia.[2] Second generation antipsychotics followed 
and were considered superior to first generation because they did not have the intense 
neurological side effects, but the second generation drugs had their own problem. When 
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taken over a long period of time like antipsychotics are prescribed for, the second 
generation drugs were found to increase weight gain, increase prevalence for 
cardiovascular risk factors and lead to metabolic abnormalities.[2] These are factors that 
contribute to the average life span of severely mentally ill patients being 25 years 
shorter than the rest of the population.[2] While antipsychotics are a good fill in, they are 
far from perfect. The important step in antipsychotic medicine is going be when the drug 
can attack the disease at its source, and not by blocking some of the body’s natural 
processes.  
 
Conclusion and Future Treatment 
 Schizophrenia is a disease that mankind has been unable to figure out. For a 
long time it was not understood, but that is beginning to change. If the mechanism 
proposed in this paper is correct then it could potentially provide an explanation for why 
fMRIs show overstimulation of the amygdala when schizophrenics are faced with 
emotional distraught. If postsynapses become linked then a stimuli could move laterally 
through a neuron and create bilateral amygdala stimulation when it is meant to be only 
right amygdala stimulation. If this mechanism can be confirmed then the treatment for 
schizophrenia would change dramatically. With fMRIs showing where there is abnormal 
overstimulation in the brain, medicines could be created to target those plasma 
membrane linkages and sever them from each other. If the mechanism is not confirmed 
the potential of the epigenetic control of schizophrenia is another area that research 
could investigate. By pairing fMRI and genetic screens, pre-episode diagnosis of 
schizophrenia would be possible and would allow for preemptive treatment. Ideally 
these strategies would push antipsychotic drugs out of schizophrenia treatment 
altogether.  
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